Display Settings:

Format

Send to:

Choose Destination
    Malar J. 2010 Jul 22;9:212.

    The pharmaceutical death-ride of dihydroartemisinin.

    Source

    Fondation ACT-ion Afrique, Brussels, Belgium. fhjansen@actionafrique.com

    Abstract

    In the 2010 second edition of WHO's guidelines for the treatment of malaria, the relatively new fixed dose combination dihydroartemisinin-piperaquine is included as one of the recommended artemisinin combination therapies. However, experimental testing demonstrates that, due to its intrinsic chemical instability, dihydroartemisinin is not suitable to be used in pharmaceutical formulations. In addition, data show that the currently available dihydroartemisinin preparations fail to meet the internationally accepted stability requirements. At a time when many efforts aim to ban counterfeit and substandard drugs from the malaria market, the obvious question rises how WHO and public-private partnerships, such as Medicine for Malaria venture (MMV), can support the production and marketing of anti-malarial drugs that do not even meet the International Pharmacopoeia requirements?

    PMID:
    20649950
    [PubMed - indexed for MEDLINE]
    PMCID: PMC2916014
    Free PMC Article

    Images from this publication.See all images (2) Free text

    Figure 2
    Figure 1

      Supplemental Content

      Click here to read Click here to read

      Chemical compound information

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk